Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy
European Journal of Cancer2019Vol. 118, pp. 35–40
Citations Over TimeTop 10% of 2019 papers
Laura D. Locati, Alessandro Piovesan, Cosimo Durante, Marco Bregni, Maria Grazia Castagna, Stefania Zovato, Massimo Giusti, Toni Ibrahim, Efisio Puxeddu, Guido Fedele, Gabriella Pellegriti, Gaetana Rinaldi, Dario Giuffrida, Francesco Verderame, Federica Bertolini, Cristiana Bergamini, Alice Nervo, Giorgio Grani, Silvia Rizzati, Silvia Morelli, Ivana Puliafito, Rossella Elisei
Related Papers
- → Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model(2022)7 cited
- → Lenvatinib Approved for Certain Thyroid Cancers(2015)10 cited
- → Current status and future perspectives of molecular targeting treatment for thyroid cancer(2015)
- → THE EFFECT OF LENVATINIB AND PEMBROLIZUMAB ON THYROID CANCER REFRACTORY TO IODINE 131I SIMULATED BY MATHEMATICAL MODELING(2022)
- → Treatment for advanced differentiated thyroid cancer with multiple distant me-tastases (case report)(2023)